An Open-label Phase I Study Evaluating the Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs - The COOPERATE-1 Study.
Phase of Trial: Phase I
Latest Information Update: 30 Dec 2014
At a glance
- Drugs Everolimus (Primary) ; Pasireotide (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Adverse reactions
- Acronyms COOPERATE-1
- Sponsors Novartis Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 22 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Dec 2013 Planned end date changed from 1 Dec 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov.